肌肉减少症并非接受同步放化疗或放疗的宫颈癌患者预后的预测因素。
Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy.
作者信息
Matsuoka Hirofumi, Nakamura Keiichiro, Matsubara Yuko, Ida Naoyuki, Nishida Takeshi, Ogawa Chikako, Katsi Kuniaki, Kanazawa Susumu, Masuyama Hisashi
机构信息
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
出版信息
Anticancer Res. 2019 Feb;39(2):933-939. doi: 10.21873/anticanres.13196.
BACKGROUND/AIM: The objective of this study was to determine if sarcopenia was a predictor of poor prognosis in patients with cervical cancer (CC) undergoing concurrent chemoradiation therapy (CCRT) or radiation therapy (RT).
MATERIALS AND METHODS
A total of 236 patients with CC undergoing CCRT or RT were retrospectively examined. We determined if clinical characteristics and survival were correlated with pretreatment sarcopenia, measured as psoas muscle index (PI) or skeletal muscle index (SMI).
RESULTS
Pretreatment PI and SMI were related to parametrial involvement with CC undergoing CCRT or RT (p=0.002, and, p=0.034, respectively). The median progression-free survival (PFS) and overall survival (OS) times in patients undergoing CCRT or RT were 29.0 and 34.5 months, respectively. Neither PI nor SMI were prognostic predictors in patients with CC undergoing CCRT or RT.
CONCLUSION
Sarcopenia is not a predictive factor of outcome in patients with CC undergoing CCRT or RT.
背景/目的：本研究的目的是确定肌肉减少症是否是接受同步放化疗（CCRT）或放疗（RT）的宫颈癌（CC）患者预后不良的预测指标。
材料与方法
对236例接受CCRT或RT的CC患者进行回顾性研究。我们确定临床特征和生存率是否与治疗前的肌肉减少症相关，肌肉减少症通过腰大肌指数（PI）或骨骼肌指数（SMI）来衡量。
结果
治疗前PI和SMI与接受CCRT或RT的CC患者的宫旁组织受累情况相关（分别为p = 0.002和p = 0.034）。接受CCRT或RT的患者的无进展生存期（PFS）和总生存期（OS）的中位数分别为29.0个月和34.5个月。PI和SMI均不是接受CCRT或RT的CC患者的预后预测指标。
结论
肌肉减少症不是接受CCRT或RT的CC患者预后的预测因素。
Zotero 插件